Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II Trial of Nivolumab in Advanced Solid Tumors Based on Genomic Profiling: BELIEVE Trial (NCCH1901) Subcohort.

Cancer science·2026
Same author

Earlier Comprehensive Cancer Genomic Profiling in Gynecologic Cancers May Facilitate Genotype-Matched Therapy: A Prospective Single-Institution Study.

Obstetrics and gynecology international·2026
Same author

Real-world characterization of patients with advanced or metastatic liposarcoma, including dedifferentiated liposarcoma, in Japan in the MASTER KEY project.

Japanese journal of clinical oncology·2026
Same author

Evaluating the potential to predict chemotherapy-induced nausea and vomiting in carboplatin-containing treatment based on symptoms induced by prior cisplatin-containing treatment.

Scientific reports·2026
Same author

Impact of baseline regular magnesium oxide administration on chemotherapy-induced constipation during cisplatin-containing treatment.

International journal of clinical oncology·2025
Same author

Evaluation of factors associated with clinically problematic hiccups in cisplatin-containing treatment with dexamethasone and neurokinin 1 receptor antagonists.

International journal of clinical oncology·2025

Related Experiment Video

Updated: Jul 5, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

[Non-small-cell lung cancer].

Hirotoshi Akita1, Ichiro Kinoshita

  • 1Dept. of Medical Oncology, Hokkaido University Graduate School of Medicine, Kita-ku, Sapporo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 20, 2008
PubMed
Summary

Molecular targeted therapy combined with chemotherapy shows mixed results for advanced non-small cell lung cancer (NSCLC). Bevacizumab improved survival, while gefitinib and erlotinib did not significantly enhance outcomes in chemotherapy-naive patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) presents treatment challenges.
  • Molecular targeted therapies are increasingly investigated for NSCLC.

Purpose of the Study:

  • To evaluate the efficacy of molecular targeted therapy in combination with chemotherapy or radiotherapy for advanced NSCLC.
  • To compare survival outcomes of different targeted therapy combinations against standard treatments.

Main Methods:

  • Clinical trials were reviewed, focusing on combinations of targeted therapies (gefitinib, erlotinib, bevacizumab, multi-target TKIs, anti-EGFR antibodies) with chemotherapy or thoracic radiotherapy.
  • Patient populations included chemotherapy-naive individuals with advanced NSCLC.

Main Results:

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Experiment Videos

Last Updated: Jul 5, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

  • Gefitinib or erlotinib plus chemotherapy did not improve survival compared to chemotherapy alone in chemotherapy-naive patients.
  • Bevacizumab plus chemotherapy demonstrated improved survival in chemotherapy-naive advanced NSCLC, excluding squamous cell carcinoma.
  • Ongoing trials are investigating multi-target tyrosine kinase inhibitors and anti-EGFR antibodies in combination regimens.

    • Conclusions:

    • Bevacizumab offers a survival benefit when combined with chemotherapy in specific advanced NSCLC patient groups.
    • The efficacy of other molecular targeted therapies in combination varies, necessitating further research and clinical trials.